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Abstract
Objective: To assess the 18-month field effectiveness on severe events of a pediatric package
combining early HIV-diagnosis and targeted cotrimoxazole prophylaxis in HIV-infected children
from age six-week before the antiretroviral era, in Abidjan, Côte d'Ivoire.
Methods: Data from two consecutive prevention of HIV mother-to-child transmission programs
were compared: the ANRS 1201/1202 Ditrame-Plus cohort (2001–2005) and the pooled data of
the ANRS 049a Ditrame randomized trial and its following open-labeled cohort (1995–2000), used
as a reference group. HIV-infected pregnant women ≥ 32–36 weeks of gestation were offered a
short-course peri-partum antiretroviral prophylaxis (ZDV in Ditrame, and ZDV ± 3TC+single-
dose (sd) NVP in Ditrame-Plus). Neonatal prophylaxis was provided in Ditrame-Plus only: 7-day
ZDV and sdNVP 48–72 h after birth. A 6-week pediatric HIV-RNA diagnosis was provided on-line
in the Ditrame-Plus while it was only oriented on clinical symptoms in Ditrame. Six-week HIV-
infected children received a daily cotrimoxazole prophylaxis in Ditrame-Plus while no prophylaxis
was provided in Ditrame. The determinants of severe events (death or hospitalization > 1 day)
were assessed in a Cox regression model.
Results: Between 1995 and 2003, 98 out of the 1121 live-births were diagnosed as HIV-infected
in peri-partum: 45 from Ditrame-Plus and 53 from Ditrame. The 18-month Kaplan-Meier
cumulative probability of presenting a severe event was 66% in Ditrame-Plus (95% confidence
interval [95%CI]: 50%–81%) and 77% in Ditrame (95%CI: 65%–89%), Log Rank test: p = 0.47. After
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adjustment on maternal WHO clinical stage, maternal death, 6-week pediatric viral load, birth-
weight, and breastfeeding exposure, the 18-month risk of severe event was lower in Ditrame-Plus
than in Ditrame (adjusted Hazard Ratio (aHR): 0.55, 95%CI: 0.3–1.1), although the difference was
not statistically significant; p = 0.07). Maternal death was the only variable determinant of the
occurrence of severe events in children (aHR: 3.73; CI: 2.2–11.2; p = 0.01).
Conclusion: Early cotrimoxazole from 6 weeks of age in HIV-infected infants seemed to reduce
probability of severe events but the study lacked statistical power to prove this. Even with
systematic cotrimoxazole prophylaxis, infant morbidity and mortality remained high pointing
towards a need for early pediatric HIV-diagnosis and antiretroviral treatment in Africa.
Background
Randomized clinical trials have shown the efficacy of
short antiretroviral regimens in preventing mother to
child transmission of HIV (PMTCT) in Africa [1,2].
Despite these encouraging findings, less than 11% of HIV-
infected pregnant women had received one of these
PMTCT interventions in low-income countries in 2005
[3]. Therefore, between 570,000 and 740,000 children
became infected with HIV in 2005 worldwide. In 2005,
750,000 children died of AIDS-related diseases of whom
87% were living in sub-Saharan Africa and most had been
infected by mother-to-child transmission (MTCT) [4].
It is now urgent to improve the neglected management of
HIV-infected children to reduce paediatric mortality in
Africa. Indeed, child mortality related to HIV/AIDS is high
and occurs early in Africa because of the rapid develop-
ment of disease manifestations within the first two years
of life [5]. Mortality rates were estimated to be 35.2% by
age 1 year and 52.5% by age 2 year among HIV-infected
children in a recent African meta-analysis. As in industri-
alized countries before the antiretroviral era, the paediat-
ric HIV disease seems to follow a bimodal course in Africa
[6,7]. Thus, those children who survive beyond two years
might have a slightly slower disease progression [6,7].
In Côte d'Ivoire, the overall infant mortality rate was esti-
mated to be around 118 out of 1,000 live-births in 1998
[8]. While in Abidjan, half of HIV-infected children died
before their first birthday in the absence of highly active
antiretroviral therapy [9]. Most of these early deaths were
attributable to infectious diseases potentially preventable
by cotrimoxazole [9-11]. We therefore hypothesised that
an early prophylaxis by cotrimoxazole would help HIV-
infected children in surviving beyond their first birthday
so they would have a chance to become eligible for a spe-
cific paediatric antiretroviral therapy later on.
The benefit of cotrimoxazole is already well established in
HIV-infected adults [12-14]. In children mainly older
than 12 months, a trial has shown a significant benefit of
cotrimoxazole prophylaxis in HIV-infected children aged
1–14 years in Zambia [15]. Since 2000, cotrimoxazole
prophylaxis is recommended in HIV-exposed children
[16,17]. However, its field efficacy within the first year of
life is unknown in Africa and needs to be balanced with
the safety issue.
Within the ANRS 1201/1202 Ditrame-Plus cohort con-
ducted in Abidjan, Côte d'Ivoire, infants born to HIV-
infected mothers who received an PMTCT intervention
[18,19] were offered a paediatric package including a rou-
tine and early diagnosis of HIV infection from age 6-week
by real-time PCR [20,21] and a cotrimoxazole prophylaxis
targeted on HIV-infected infants from then.
The objective of this study was to assess the field effective-
ness of this early paediatric package on the occurrence of
severe events during the first 18 months the ANRS 1201/
1202 Ditrame-Plus cohort conducted in 2001–2005
[18,19] and compared it with a historical cohort of chil-
dren followed-up in the 1995–2000 period as a reference
group. in Abidjan, Côte d'Ivoire [9].
Methods
Study design
For this study, we compared data issued from the ANRS
1201/1202 Ditrame-Plus cohort [18,19] and the pooled
data of the ANRS 049a Ditrame randomized clinical trial
and its following open-labelled cohort from 1995 to 2000
[22-24]. During the 1995–2000 and 2001–2005 periods,
the paediatric follow-up was conducted in the same sites
and by the same clinical team following the same sched-
ule. These projects were approved by the National Ethical
Committee in Côte d'Ivoire and the institutional review
board of the French Agence Nationale de Recherches sur
le Sida (ANRS).
Population and peri-partum PMTCT intervention
The inclusion procedures and research design undertaken
in these two projects were previously described
[18,19,22,23]. Briefly, any consenting HIV-1 infected
pregnant woman aged 18 years and over, at < 32–36
weeks of gestation (and 34–36 for Ditrame), in one of the
selected community-run health facilities was eligible.
Women included were systematically proposed a peri-par-BMC Public Health 2008, 8:169 http://www.biomedcentral.com/1471-2458/8/169
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tum PMTCT antiretroviral regimen (Additional file 1:
Table 1). The maternal antiretroviral prophylaxis con-
sisted of a short-course peripartum zidovudine (ZDV) reg-
imen in the ANRS 049a DITRAME trial and a combination
of ZDV ± lamivudine (3TC) and nevirapine single dose
(NVPsd) in the Ditrame-Plus study. Neonatal prophylaxis
in the Ditrame-Plus study consisted of ZDV for 7 days and
a sdNVP 48–72 h after birth.
Postnatal PMTCT intervention
No specific postnatal intervention was provided in the
ANRS 049a Ditrame trial (Additional file 1: Table 1). At
inclusion in the ANRS 1201/1202 Ditrame-Plus cohort,
pregnant women were systematically offered two alterna-
tive options to prolonged breastfeeding: exclusive for-
mula-feeding from birth (with a drug inhibiting lactation)
or exclusive breastfeeding with early cessation within the
fourth month (short-term breastfeeding) [25,26]. The
staff supported their choice and counselled them accord-
ingly. Breastmilk substitutes were free of charge from birth
or the date of weaning until nine months of age. A system-
atic vitamin A supplementation was provided to children
according to WHO recommendations.
Paediatric diagnosis of HIV infection
HIV diagnosis was provided at 6-week on-line in the
Ditrame-Plus project while it was only oriented on clinical
symptoms in the Ditrame study. Blood samples were
taken for paediatric HIV-1 diagnosis at Day 2, week 4–6,
then three monthly until one year, month 18 and 24 and
two months after complete cessation of breastfeeding if
any. A quantitative bDNA assay (Quantiplex HIV RNA
3.0; Quantiplex, East Walpole, Massachussets, USA) was
retrospectively applied to the 1995–2000 cohort [20]. In
Ditrame Plus, a paediatric HIV-1 infection was initially
diagnosed using a commercial plasma HIV-1 RNA assay
(Versant bDNA HIV RNA kit version 3.0, Bayer diagnos-
tics, Emeryville, CA, USA) [20]. From 2003, a TaqMan
HIV-1 RNA real-time PCR test was used [21].
Paediatric HIV-1 infection was defined as a positive HIV
RNA at any age, or as a positive HIV serology if age > 18
months. The first positive test allowed the estimation of
the timing of infection: in utero if the Day-2 sample was
positive, intrapartum-early postnatal if the Day-2 sample
was negative but the 4–6-week sample positive, late post-
natal if the 4–6-week sample was negative but later sam-
ple became positive.
Cotrimoxazole prophylaxis
In the 1995–2000 period, no prophylaxis of opportunistic
infections was provided in the absence of Ivoirian guide-
lines. After a national consensus meeting held in 1999 in
Abidjan, Côte d'Ivoire and an international WHO/
UNAIDS meeting held in 2000 in Harare, Zimbabwe, we
applied the recommendations formulating that cotrimox-
azole prophylaxis should be systematically used in HIV-
infected children and in HIV-exposed infants until diag-
nosis of its own infection has been made [16,27]. From
2001, HIV-infected children received a cotrimoxazole
prophylaxis (25 mg/kg per day) systematically from six
weeks of age until at least their first birthday.
Follow-up procedures and data collection
From birth up to 18 months, systematic visits were sched-
uled on study sites for clinical, psychosocial and biologi-
cal follow-up for both mothers and infants. In both
PMTCT programs, children were seen at birth, day 2, then
at week-1, week-6, month-3 then three monthly until 18
months. At each contact, the medical staff documented
clinical events that occurred in children since the last visit
and infant feeding practices were recorded. During the
Ditrame-Plus study, children were first managed at the
day-care hospital units linked to the centres, then trans-
ferred to the University Hospital of Yopougon if overnight
care were needed. In Ditrame, there was no day-care hos-
pital. In both cohorts, children were referred to the paedi-
atric unit of the University Hospital of Yopougon for life-
threatening diseases or diseases requiring overnight care
(> one day). Care services were also available whenever
needed between scheduled visits. All transport costs were
reimbursed and all care expenses were entirely supported
by both projects.
Study outcomes
The primary outcome of the study was the occurrence of a
severe event defined as death or a hospitalisation (> one
day) related to any cause in the paediatric unit of the Uni-
versity Hospital. Mortality was also investigated separately
as a secondary outcome. Causes of death were explored in
all children. Verbal autopsies were systematically con-
ducted by trained socio-psychologists to assign a possible
cause of death in Ditrame-Plus. Probable contributing
causes of death were independently assessed by two pae-
diatricians on the basis of all the clinical information col-
lected (including hospital records) and the verbal
autopsy. A third evaluation was provided in case of disa-
greement. Clinical and haematological incidence of
adverse events graded 3 or 4 (WHO standardised toxicity
table) of cotrimoxazole were looked for systematically at
each visit in Ditrame-Plus.
Statistical analysis
All live-born infants infected with HIV in peri-partum
were included in this analysis. Late postnatal cases were
not eligible for an early cotrimoxazole prophylaxis and
excluded from the present analysis.
Baseline characteristics were compared between the
Ditrame-Plus cohort and the Ditrame historical controlBMC Public Health 2008, 8:169 http://www.biomedcentral.com/1471-2458/8/169
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cohort using Pearson χ2 test or Fisher's exact test for cate-
gorical variables, and Student's t-test or Mann-Whitney U
test for continuous variables. Maternal CD4 results were
expressed as percentage of total lymphocyte count, mater-
nal and paediatric plasma viral load were expressed in
log10/mL. The week-6 paediatric plasma viral load esti-
mate was used as considered the highest level for children
infected in peripartum [28]. In Ditrame Plus, the alloca-
tion to an infant-feeding group (formula-fed or short-
term breastfed) was based on the actual feeding option
implemented two days after birth. In Ditrame, prolonged
and unrestricted breastfeeding was the norm [29].
The cumulative probability of having a first severe event
(hospitalization > one day or death, which ever came
first) from birth was assessed using a Kaplan-Meier esti-
mation with a time-to-failure method. The date of right
censoring was the date of antiretroviral therapy introduc-
tion, or the last available date of follow-up until 18
months. An adjusted Cox proportional-hazard model was
used to study the determinants of the 18-month occur-
rence of severe events, including the ANRS 1201/1202
Ditrame-Plus paediatric package. Hazard Ratio (HR) for
severe events between the two groups was estimated with
adjustment for other known determinants of child mor-
tality and other potential confounding factors at baseline.
HRs were reported with their 95% confidence interval
(95%CI). The role of interaction terms was also investi-
gated. All statistical analyses were carried out with the use
of SAS software (version 8.2; SAS Institute, Cary, North
Carolina, USA).
Results
Study population
Out of the 1164 HIV-infected pregnant women included
between September 1995 and July 2003, 1103 (729 from
Ditrame Plus and 374 from Ditrame) gave birth to 1121
live-births. Of these, 141 were diagnosed as HIV-infected
during the first 18 months follow-up (Figure 1). After
exclusion of the late postnatal transmission cases and the
second and third born babies of multiple birth outcomes,
98 peripartum HIV-infected children were included in the
present analysis: 45 were issued from the Ditrame-Plus
project (25 exposed to maternal ZDV+NVPsd and 20 to
ZDV+3TC+NVPsd) and 53 constituted the historical con-
trol group (23 exposed to maternal placebo before 1998,
and 30 to maternal ZDV).
Baseline and follow-up characteristics
Before delivery, mothers of HIV-infected children from
the Ditrame-Plus cohort were significantly more advanced
in HIV-disease than those from the Ditrame control
cohort (Additional file 1: Table 2): they were more likely
classified WHO clinical stage 3–4, more immune-sup-
pressed (median difference: -165 CD4+ cell count) and
had a higher viral load (mean difference: +0.3 log).
Twenty children (44.4%) were formula-fed from birth in
the Ditrame-Plus cohort and only two (3.8%) in Ditrame.
HIV-infected children in the Ditrame-Plus cohort were
significantly more likely to have been infected during the
in-utero period than children in the Ditrame trial, 53.3%
and 11.3%, respectively (p < 0.01). The median baseline
6-week paediatric plasma viral load at HIV-diagnosis was
significantly higher in Ditrame-Plus compared to
Ditrame, with a mean difference of 0.4 log. There was no
statistical difference between the two groups for other
socio-demographic, clinical and biological baseline char-
acteristics. Among the 45 HIV-infected children from
Ditrame-Plus, 31 (69%) had at least one CD4+ cell per-
centage measurement at a median age 3-month. Their
median CD4 percentage was 18% (range: 6%–37%).
The median follow-up duration from birth was 12.1
months among Ditrame-Plus children and 8.7 months in
the Ditrame trial (p = 0.13). Two children (4.4%) and five
children (9.4%) were lost-to-follow-up by age 18-month
in the Ditrame-Plus cohort and the Ditrame trial respec-
tively. Nine of the 45 Ditrame-Plus children (20%)
received an antiretroviral therapy initiated at a median age
of 5.5 months and were right-censured whereas none were
treated before age 18-month in Ditrame. Over the first 18-
months, five maternal deaths were recorded of whom four
occurred in the Ditrame-Plus cohort.
Occurrence of severe events
Among the 98 HIV-infected children, 64 severe events
occurred during the first 18 months of life: 26 in the 45
Ditrame-Plus children and 38 out of the 53 Ditrame-chil-
dren. The Kaplan-Meier cumulative probabilities of pre-
senting a severe event did not differ significantly between
the two cohorts (Figure 2, Log Rank, p = 0.47): at 12-
month, 56% (95%CI: 41%–72%) in Ditrame-Plus and
63% (95%CI: 49%–76%) in the control group; and at 18-
month, 66% (95%CI: 50%–81%) in Ditrame-Plus and
77% (95%CI: 65%–89%) in the control group. After
adjustment on maternal WHO clinical staging, maternal
death as a time dependant variable, 6-week paediatric
viral load, low birth-weight, and breastfeeding exposure,
the risk of severe event over the first 18 months tended to
be lower in Ditrame-Plus than in Ditrame, but this trend
did not reach the statistical difference (aHR: 0.55; 95%CI:
0.3–1.1; p = 0.07). Maternal death as time dependant var-
iable was the only variable significantly associated with
the occurrence of severe events in children (aHR: 3.73; CI:
2.2–11.2; p = 0.01) (Additional file 1: Table 3).
Mortality
Overall, there were 23 deaths out of the 45 children from
the Ditrame-Plus cohort and 34 out of the 53 in the
Ditrame group. Survival did not differ significantlyBMC Public Health 2008, 8:169 http://www.biomedcentral.com/1471-2458/8/169
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between these two groups of HIV-infected children: the
12-month Kaplan-Meier probability of death were 50%
(95%CI: 34%–66%) in Ditrame-Plus and 59% (95%CI:
45%–72%) in the control group; at 18-month, they were
60% (95%CI: 44%–77%) in Ditrame-Plus and 69%
(95%CI: 56%–82%) in Ditrame (Log Rank, p = 0.49). Pri-
mary causes of death tended to differ between the two
cohorts: Diarrhoea was the main cause of mortality in
Ditrame-Plus (43%) and was more often reported than in
controls (p = 0.03), while the leading cause of death
reported in Ditrame was pneumonia (41%). Other causes
of death were comparable between the two cohorts (Addi-
tional file 1: Table 4).
Safety
Among the 45 HIV-infected children who received cotri-
moxazole in Ditrame-Plus, no clinical grade 3 or 4 adverse
event (dermatologic or Lyell Syndrome) attributable to
cotrimoxazole was reported. The incidence rate of severe
neutropenia (< 1000/mm3) was 20 per 100 child-years of
cotrimoxazole follow-up (N = 8). The incidence rate of
grade 3 or 4 thrombocytopenia (< 100 000/mm3) and
anaemia (< 8 g/dL) were 28 (N = 11) and 51 (N = 14) per
Cohort profile of children included in the ANRS 049a DITRAME trial and its open cohort and the ANRS 1201/1202  DITRAME-PLUS cohort Figure 1
Cohort profile of children included in the ANRS 049a DITRAME trial and its open cohort and the ANRS 1201/
1202 DITRAME-PLUS cohort. 1995–2005.
Women who delivered in 
ANRS 1201/1202 DITRAME 
PLUS 
N = 729 
Women who delivered in 
ANRS 049a DITRAME and its 
open cohort  
N = 374 
Pregnancy outcomes 
N = 767 
Pregnancy outcomes 
 N = 379 
Peripartum infected 
children  
 (N = 53) 
Stillbirths 
(N = 13) 
Peripartum infected 
children  
(N = 45) 
2
nd or 3
rd from 
mutiple birth 
and infected  
(N = 1) 
HIV-infected children 
(N = 61) 
HIV-infected children 
 (N = 80) 
Stillbirths 
 (N = 7) 
2
nd or 3
rd from 
mutiple birth 
and infected  
(N = 1) 
Postnatal 
infection or 
timing 
unknown 
(N = 15) 
Postnatal 
infection or 
timing 
unknown 
 (N = 26) BMC Public Health 2008, 8:169 http://www.biomedcentral.com/1471-2458/8/169
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100 child-years respectively. Among the 12 blood cultures
available, 50% found germs resistant to cotrimoxazole.
Discussion
We compared pooled data collected over two successive
west-African PMTCT cohorts conducted in a similar envi-
ronment to assess the field effectiveness of a specific pae-
diatric set of interventions combining early HIV-diagnosis
in all HIV-exposed newborns from age 6-week and cotri-
moxazole prophylaxis targeted to those HIV-infected.
Early virological HIV-diagnosis was routinely feasible in
Ditrame-Plus, and despite the systematic daily cotrimoxo-
zole prophylaxis, the occurrence of severe events
remained extremely high reaching 66% at 18 months of
age. These residual severe events remained also mainly
attributable to infectious causes. After adjustment on
Kaplan-Meier probability of 18-month occurrence of severe events (hospitalization > one day or death) in 98 peri-partum HIV- children children in the ANRS 049a DITRAME and ANRS 1201/1202 DITRAME PLUS projects Figure 2
Kaplan-Meier probability of 18-month occurrence of severe events (hospitalization > one day or death) in 98 
peri-partum HIV-children children in the ANRS 049a DITRAME and ANRS 1201/1202 DITRAME PLUS 
projects. Abidjan, Côte d'Ivoire. 1995–2005.
Age (days)  6-week  3-month  6-month  9-month  12-month  18-month 
Children at risk (n)         
  DITRAME  53  48 32 21 18 11 
  DITRAME-PLUS  45  39 27 18 15 11 
Cumulative SE (n)         
  DITRAME  0  3  18 28 31 38 
  DITRAME-PLUS  0  5  11 18 20 26 
Cumulative probability of 
  SE (95% CI) 
       
 DITRAME   
0.00 
(-) 
0.06 
(0.00 - 0.12)
0.36 
(0.23 - 0.49)
0.56 
(0.43 - 0.70) 
0.63 
(0.49 - 0.76)
0.77 
(0.65 - 0.89)
 DITRAME-PLUS 
0.00 
(-) 
0.13 
(0.03 - 0.23)
0.29 
(0.16 - 0.43)
0.48 
(0.32 - 0.63) 
0.56 
(0.41 - 0.72)
0.66 
(0.50 - 0.81)
SE: Severe event: death or hospitalization; 95% CI: 95% confidence interval.  BMC Public Health 2008, 8:169 http://www.biomedcentral.com/1471-2458/8/169
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known determinants of child morbidity-mortality, the
daily cotrimoxazole provided to HIV-infected children
was well tolerated and reduced by 45%, although not sig-
nificantly, the occurrence of severe morbidity-mortality
when compared to the control group. The effectiveness of
cotrimoxazole prophylaxis for optimizing early case man-
agement of HIV-infected infants and reducing severe mor-
bidity-mortality within their first year of life was not
statistically significant within our study. In fact, the statis-
tical power estimated to show an existing difference
between the two cohorts was estimated to be only 11%.
As the access to care was different between the two cohorts
with no day-care hospital in Ditrame while this existed in
the Ditrame Plus cohort, .some of the Ditrame plus chil-
dren were first managed at the day-care hospital before
going back to home on the same day or to be hospitalised
at the pediatric unit if overnight care was needed. To get
the most comparable definition of hospitalisation
between the two cohorts, we defined hospitalisation as a
hospitalisation > one day, at the pediatric unit of the
Yopougon Hospital for both cohorts. Consequently, we
feel that we have minimized the potential information
bias in documenting comparably the risk of severe event.
The 6-week MTCT rates were about 15% in the Ditrame
trial [30] while it was 5% in the Ditrame-Plus cohort,
explained by a greater efficacy of PMTCT interventions in
Ditrame-Plus [18] but also leading to the likely selection
of HIV-infected newborns at higher risk of rapid disease
progression. At inclusion in Ditrame-Plus, mothers from
HIV-infected children were more advanced in the HIV/
AIDS disease, more immune-suppressed, and their
infected children were more likely to have been infected
earlier (in utero). Therefore, we observed a trend of a pro-
tective effect of cotrimoxazole in Ditrame-Plus HIV-
infected children having a poorer prognosis than children
from Ditrame.
In the Ditrame-plus cohort, 20% of the children started an
antiretroviral therapy as they were symptomatics, with a
likely higher risk of experiencing a severe event: if these
children would have not been right censored at the time
of starting antiretroviral therapy in our analysis, this
would have led to a probably lower risk of severe event in
the ditrame plus cohort compared to the ditrame cohort
but attributable to the ART effect rather than the cotrimox-
azole effect, so with an overestimation of the cotrimoxa-
zole effect.
We conclude that we have underestimated the true cotri-
moxazole protective effect: we hypothesize the cotrimox-
azole protective effect would have in fact probably exist
with a greater public health impact if it was administrated
to HIV-infected infants with a less severe HIV disease than
in Ditrame-Plus and issued from HIV-infected mothers
who would have received a less effective PMTCT interven-
tion than the Ditrame-Plus antiretroviral combination.
So, this would even have a greater impact in population
with a lower standard of care access than in our well struc-
tured research context.
The ideal study design to assess the efficacy of cotrimoxa-
zole prophylaxis given early in newborn would have been
a randomized placebo controlled trial. Despite the lack of
evidence of cotrimoxazole's effectiveness specifically in
African infants less than 12 months in the CHAP trial
[15], this would have been unethical because of the lack
of equipoise between the two randomised cotrimoxazole
and placebo arms as cotrimoxazole was already
demondtrated to be efficacious in children older than 12
months [15] and in adults [13]. Based on these latter find-
ing, the good clinical practice was to provide the recom-
mended standard of care to all study participants:
national guidelines recommend cotrimoxazole prophy-
laxis in children since 1999 in Côte d'Ivoire [27]. We
choose this historical comparison to assess the cotrimox-
azole effectiveness adjusting for the other known progno-
sis factors of infant mortality. We acknowledge that
although important confounding variables such as mater-
nal clinical stage of disease, 6-week paediatric viral load,
birth-weight, breastfeeding were systematically controlled
for in the analysis, this potential confusion was only
partly taken into account notably because infant CD4 cell
count was not available in the Ditrame study. Finally, the
low rates of lost-to-follow-up of these HIV-infected chil-
dren were acceptable in this difficult context and strength-
ened our conclusion.
The infant mortality figures among HIV-infected children
reported in the Ditrame and Ditrame-Plus projects (59%
and 50% respectively) were higher than those reported in
a pooled analysis in which 35% of African children with
early HIV-infection had died by age one year [5]. The dif-
ference could be due to the large proportion of South Afri-
can children in this pooled analysis, where infant
mortality rate was reported to be lower than in West Africa
according to 1998 demographic health surveys [5].: i.e. 59
per 1,000 livebirths in South Africa [31] versus 118 per
1,000 in Côte d'Ivoire [8]. Our results suggest a reduced
incidence of pneumonia as cause of death but a significant
higher rate of diarrhoea as cause of death was observed in
Ditrame-Plus compared to Ditrame. About 40% of the
Ditrame-Plus children were formula-fed while their HIV-
status was not yet ascertained, exposing formula-fed HIV-
infected children to an increased mortality risk. Formula-
feeding was not retained as a significant explaining factor
for morbidity-mortality in our adjusted analysis, but HIV-
infected children who are still breastfed at the time ofBMC Public Health 2008, 8:169 http://www.biomedcentral.com/1471-2458/8/169
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HIV-diagnosis should better continue to be breastfed as
recently reported elsewhere [32] and recommended [33].
As in others studies, our results confirm maternal death as
the major determinant of infant mortality suggesting the
crucial role of caregivers including mothers in the access
to care for children in Africa [5,34]. These findings thus
emphasise the need for an early HIV-diagnosis, and an
adequate access to antiretroviral care and support for HIV-
infected children and all members of affected families,
including mothers [3].
Cotrimoxazole demonstrated its efficacy in 2004 in a
Zambian trial conducted among children mainly older
than 12 months [15]. In two South African studies, the
history of cotrimoxazole use was significantly lower in
children with severe pneumonia attributable to Pneumo-
cystis jiroveci than those without [35,36]. Lastly, HIV-
infected infants with access to cotrimoxazole prophylaxis
had a significantly lower incidence of pneumonia than
those without access to prophylaxis [37]. Our results are
consistent with the Zambian and South African results
observed in older children and reinforce the message sug-
gesting that all HIV-infected children should receive cotri-
moxazole prophylaxis in low-income settings, irrespective
of their age. In 2006, WHO recommends that all infants
exposed to HIV should receive cotrimoxazole prophylaxis
from six weeks until HIV infection is excluded (rarely
before 18 months in routine) [17].
While the number of antiretroviral-treated adults in low-
income countries is increasing in Africa with the World
Health Organization (WHO) 3 × 5 initiative since 2003, it
is estimated that only 15% of people in need of antiretro-
viral treatment in 2005 are covered [38]. There is particu-
larly a lack of access to antiretroviral therapy in African
children [3]. The lack of routine available access to an
early diagnosis of HIV-infection in children may explain
this delayed access to antiretroviral therapy [39]. In our
setting, the real-time PCR test used was low cost (10
euros/sample) and highly accurate [21]. The cost of pro-
viding systematically a daily cotrimoxazole prophylaxis to
any HIV-exposed child (3 euros/month) during their first
year of life is estimated to be (100*10 months*3) = 3000
euros for 100 HIV-exposed children. When using a tar-
geted strategy guided by the early paediatric HIV-diagno-
sis (10 euros per unit), given the hypothesis of a 5%
mother-to-child transmission rate, the cost for diagnosing
100 HIV-exposed children and providing to HIV-infected
children a daily cotrimoxazole prophylaxis during their
first year of life is estimated to be [(100*10)+(5*10
months*3)] = 1150 euros for 100 HIV-exposed children.
Thus, not only is the cost of the targeted strategy more
affordable, but also will it allow detecting early HIV-
infected children to give them an opportunity to access to
antiretroviral therapy.
Conclusion
To conclude, early cotrimoxazole from 6 weeks of age in
HIV-infected infants seemed to reduce probability of
severe events but the study lacked statistical power to
prove this. Even with systematic cotrimoxazole prophy-
laxis, infant morbidity and mortality remained high. Our
results highlight the expected interest of early antiretrovi-
ral therapy in HIV-infected children less than 12 months
of age, as this was already reported from several studies
conducted in developed countries [40-42]. This early
antiretroviral therapy has recently demonstrated a benefit
on infant survival in South Africa [43]. Our results argued
that an early and reliable pediatric HIV-diagnosis from age
6-week could better reduce the burden of pediatric HIV-
infection in giving a universal opportunity of access to cot-
rimoxazole prophylaxis and antiretroviral therapy for
them and their family.
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